AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.FDA Updates Atazanavir Sulfate Capsule Labeling
“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes.
“Section 5 Warnings and Precautions was revised to include cholelithiasis ...
“In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added.
“In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press rele...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 12, 2013 Category: Infectious Diseases Source Type: news
HHS Adult and Adolescent Antiretroviral Treatment Guidelines Updated
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announces the release of the updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Key additions and revisions to the guidelines include:
Updated recommendation on integrase strand transfer inhibitor (INSTI) resistance testing in individuals failing an INSTI-based regimen
Guidance on use of a newly available genotypic tropism assay to predict HIV-1 coreceptor usage
Updated recommendations on initiation of antiretroviral therapy (ART) in treatment-naive individuals
Updates to What to Star...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 12, 2013 Category: Infectious Diseases Source Type: news
FDA Updates Darunavir Tablet and Oral Suspension Labeling with Pediatric Dosing Information
“On February 1, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to include once daily dosing in treatment-naïve subjects 3 to less than 18 years of age and once daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Darunavir (Prezista) patient drug summary (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A S...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 7, 2013 Category: Infectious Diseases Source Type: news
Explore the Updated AIDSinfo and infoSIDA Mobile Sites
Check out our updated AIDSinfo and infoSIDA mobile sites!
Updates include the following:
New design that evokes the look and feel of an app
Reorganized content to match the display on the redesigned AIDSinfo and infoSIDA websites
Improved navigation to make information easier to access
Addition of the news section and e-newsletter sign-up page
Improved access to Facebook and Twitter links
Addition of a home page image slideshow to highlight new and updated website content
Improved search engine optimization (SEO) to make it easier for Google and other search engines to index content on t...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 7, 2013 Category: Infectious Diseases Source Type: news
February 7 is National Black HIV/AIDS Awareness Day
AIDSinfo joins individuals and organizations across the nation in observing National Black HIV/AIDS Awareness Day. The awareness day is set aside each year to acknowledge the disproportionate burden of HIV/AIDS in the African-American community. In 2009, according to CDC, African Americans represented 14% of the U.S. population but accounted for 44% of all new HIV infections.
To learn more about HIV/AIDS and African Americans, please explore our National Black HIV/AIDS Awareness Day webpage [en español]. (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 7, 2013 Category: Infectious Diseases Source Type: news
New Publications Available from CDC
This report presents results of analyses measuring progress toward achieving objectives of the National HIV/AIDS Strategy for the United States and the Division of HIV/AIDS Prevention of CDC Strategic Plan. It is a supplement to the 2010 HIV Surveillance Report.
Background Brief on the Prevention Benefits of HIV Treatment. This brief explores the concept and strategy of treatment as prevention—treating HIV-infected people with antiretroviral medications to benefit their health and also to reduce their risk of transmitting HIV to others.
HIV among Pregnant Women, Infants, and Children in...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 1, 2013 Category: Infectious Diseases Source Type: news
FDA Updates Complera Labeling with New Indication and Clinical Trial Information
“On January 25, 2013, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) package insert. The major changes include restricting the indication to treatment-naïve adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL, updating the package insert with the 96 week results from the Phase 3 trials and adding a new Contraindication and new Warning and Precaution for hepatotoxicity.”
More information is available:
FDA: Press release
FDA: Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) label (PDF) (Source: AIDSinfo At-a-Glance: ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 1, 2013 Category: Infectious Diseases Source Type: news
Correction to Dosing Recommendation in the Perinatal Guidelines Clarified
A recent change to the Perinatal Guidelines was further clarified on January 29, 2013. To see the clarification regarding the nevirapine (NVP) dosing recommendation in Table 9. Recommended Neonatal Dosing for Prevention of Mother-to-Child Transmission of HIV, please view the correction notice. (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 1, 2013 Category: Infectious Diseases Source Type: news
FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included.
"Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding
"Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news
Corrections to the Perinatal Guidelines
On January 22, 2013, changes were made to the Perinatal Guidelines to clarify the infant nevirapine (NVP) dosing recommendations.
In the Postpartum Care—Infant Antiretroviral Prophylaxis section, Table 9. Recommended Neonatal Dosing for Prevention of Mother-to-Child Transmission of HIV was updated to indicate that the NVP prophylaxis doses are presented as the total dose (not mg/kg). (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news
CDC Releases Supplement to the 2010 HIV Surveillance Report
This report provides data on diagnoses of HIV infection during 2010 and data on people living with a diagnosis of HIV infection at the end of 2009 for adults and adolescents in the United States and Puerto Rico who live in metropolitan areas with a population of 500,000 or more. It is a supplement to the 2010 HIV Surveillance Report. (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 18, 2013 Category: Infectious Diseases Source Type: news
AIDSinfo Releases HIV/AIDS Glossary App for Android Devices
Our popular AIDSinfo HIV/AIDS Glossary iPhone app is now available for Android devices! This app provides on-the-go access to definitions for more than 700 HIV/AIDS-related terms in English and Spanish—the same terms found in the AIDSinfo 7th edition Glossary of HIV/AIDS-Related Terms. The app also includes an audio feature that provides users with the pronunciation for each glossary term. Visit the AIDSinfo Apps page to download the app for your Android or Apple (iPhone, iPad, and iPod Touch) device today.
AIDSinfo welcomes feedback on the glossary app for Android devices. Please send comments to ContactUs@aidsinfo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 18, 2013 Category: Infectious Diseases Source Type: news
FDA Presents Webinar on Draft Guidance on Vaginal Microbicides for the Prevention of HIV Infection
“On Tuesday, January 22, 2013, from 2:00 - 3:00PM (ET), FDA will present a webinar to discuss the recently published draft guidance for industry entitled, 'FDA Guidance for Industry Webinar on Draft Guidance Vaginal Microbicides: Development for the Prevention of HIV Infection' …
“This webinar will focus on select sections of the guidance including:
Clinical considerations in early phase development
key safety considerations including safety data in specific populations such as pregnant women and adolescents,
Phase 3 trial design issues,and
risk-benefit considerations.
“Oth...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 18, 2013 Category: Infectious Diseases Source Type: news
Study Examines Bone Mineral Density in Children and Adolescents with Perinatal HIV Infection
The objective of the study is to] estimate prevalence of low bone mineral density (BMD) in perinatally HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) children, and to determine predictors of BMD in HIV+. … 350 HIV+ and 160 HEU were enrolled. Mean age was 12.6 and 10.7 years for HIV+ and HEU, respectively. Most (87%) HIV+ were receiving HAART. More HIV+ than HEU had total body and lumbar spine Z-scores less than -2.0 (total body: 7 vs. 1%, P=0.008; lumbar spine: 4 vs. 1%, P=0.08). Average differences in Z-scores between HIV+ and HEU were attenuated after height and/or weight adjustment. Among HIV+, total bo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 4, 2013 Category: Infectious Diseases Source Type: news
FDA Approves First Anti-Diarrheal Drug for People with HIV/AIDS
“The U.S. Food and Drug Administration … approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.
“Diarrhea is experienced by many HIV/AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies. Fulyzaq is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite. Patients take Fulyzaq two times a day to manage watery diarrhea due to the secretion of electrolytes and water in the gastro...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 4, 2013 Category: Infectious Diseases Source Type: news
